Is Editas Medicine Inc (EDIT) overvalued?
Editas Medicine Inc (EDIT) is a biotechnology company listed on NASDAQ.
This page asks whether Editas Medicine Inc (EDIT) looks expensive on cached numbers — not a short thesis.
Latest reported EDIT revenue for 2024-12-31 was $32.3M. Net income was -$237.1M. Revenue was down 58.6% from 2023-12-31 to 2024-12-31. EDIT currently screens at market cap $375.2M.
EDIT currently screens at market cap $375.2M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next EDIT 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the EDIT stock page for the full model, not this heading.
Not investment advice.